Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Lowered to "Sell" at StockNews.com

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) was downgraded by StockNews.com from a "hold" rating to a "sell" rating in a note issued to investors on Thursday.

Oramed Pharmaceuticals Stock Up 0.9 %

NASDAQ:ORMP traded up $0.02 during mid-day trading on Thursday, reaching $2.21. 129,478 shares of the company were exchanged, compared to its average volume of 110,599. Oramed Pharmaceuticals has a 12 month low of $2.00 and a 12 month high of $3.67. The stock has a market cap of $89.09 million, a PE ratio of 20.09 and a beta of 1.66. The company has a fifty day moving average of $2.36 and a 200 day moving average of $2.38.

Hedge Funds Weigh In On Oramed Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in ORMP. World Equity Group Inc. acquired a new position in Oramed Pharmaceuticals during the fourth quarter valued at approximately $48,000. XTX Topco Ltd increased its position in shares of Oramed Pharmaceuticals by 59.7% in the 3rd quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company's stock valued at $60,000 after buying an additional 9,242 shares in the last quarter. Marquette Asset Management LLC acquired a new stake in Oramed Pharmaceuticals during the 4th quarter worth $81,000. Dimensional Fund Advisors LP lifted its holdings in Oramed Pharmaceuticals by 52.1% during the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company's stock worth $81,000 after acquiring an additional 10,774 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in Oramed Pharmaceuticals in the third quarter valued at about $272,000. Institutional investors and hedge funds own 12.73% of the company's stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.